CleaRank Financial AI • AI-powered analysis using real-time market data from TwelveData
Analysis reviewed by Kate Leaman, Financial Journalist and Market Analyst. Data refreshed daily. Not financial advice.
DexCom Inc. (DXCM) is currently trading at $83.45, below its 50-day SMA of $87.38 but above its 200-day SMA of $73.77, indicating a mixed technical picture. The company has a strong track record of beating earnings estimates, with its most recent report on July 30, 2026, showing an EPS beat of 14.75% and a subsequent price increase of 11.95%. Analysts maintain a strong 'Buy' consensus with a median price target of $95.00, suggesting an upside of 13.8% from current levels. The company operates in the Healthcare sector, specifically Medical Devices, which has a median P/E of 31.9 and median revenue growth of 8.1%. DXCM's own P/E of 33.75 is slightly above the sector median, but its profit margin of 20.12% and return on equity of 38.49% significantly outperform sector averages. The company's revenue growth of 13.1% also exceeds the sector median. Despite the positive fundamental outlook and strong analyst support, recent insider activity shows a net selling trend, with total sales of $16.1M versus purchases of $1M. The company's forward growth estimates remain strong, with projected revenue growth of 11.00% for the next quarter and 12.00% for the current year. Key risks include the current technical positioning below key moving averages and the moderate insider selling, which could signal short-term caution among management.
DXCM at a glance
DexCom Inc. (DXCM): Buy, 76/100 on CleaRank's AI score.
TrendMixed: the price is above its 200-day but below its 50-day moving average ($73.77 and $87.38).
EarningsDXCM beat estimates in 4 of its last 4 quarters, yet fell the next day after 1 of those beats.
InsidersInsiders sold $16.1M and bought $1.0M over the last 18 months.
ValuationP/E of 33.8 against 31.9 for the Healthcare sector: broadly in line with peers (+6%).
As of October 14, 2026, DexCom Inc. (DXCM) trades at $83.45. Wall Street's consensus target is $95.00 across 29 analysts. The 14-day RSI (daily closes) is 41, in neutral territory, and the price is below its 50-day simple moving average of $87.38.
Figures as of October 14, 2026.
Only on CleaRank
Figures we compute ourselves from DXCM's own price, earnings and insider-filing history. Tap one to see it in context.
Valuation is broadly in line with sector peers (6% difference), suggesting fair market pricing relative to industry standards.
DXCM Financial Performance
Revenue vs. Earnings
Annual
Quarterly
Earnings Reality Check
In the last 4 quarters, DXCM beat the analyst estimate 4 times; the stock fell in the first session after 1 of those beats.
DXCM earnings surprises and the stock's reaction
Report
EPS estimate
EPS actual
Surprise
First session
5 sessions
Jul 30, 2026
$0.61
$0.70
+14.75%
+11.95%
+11.38%
Apr 30, 2026
$0.47
$0.56
+19.15%
+3.02%
+2.28%
Feb 12, 2026
$0.65
$0.68
+4.62%
+7.59%
+12.29%
Oct 30, 2025
$0.57
$0.61
+7.02%
-14.63%
-14.93%
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
As of October 14, 2026, DXCM has beaten the analyst EPS estimate in 4 of its last 4 reported quarters and fell in the first trading session after 1 of those beats; its latest report, on July 30, 2026, came in 14.75% above the estimate and the stock moved +11.95% in the first session.
DXCM Analysis
Company's Health4/5
12-Month Analyst Target+13.84% above price
Median of 29 analysts (12-month)
$95.00
AI Analyst Consensus ScoreBuy
DexCom Inc. is currently trading below its 50-day SMA of $87.38 and its 20-day EMA of $85.66, but remains above its 200-day SMA of $73.77. This positioning suggests a potential short-term downtrend or consolidation phase, with the 50-day SMA acting as immediate resistance. The 14-day RSI is at 41.34, indicating neutral momentum, neither overbought nor oversold. The MACD is currently negative at -0.65, further supporting a bearish short-term technical outlook. Key support levels are near the 200-day SMA at $73.77, while resistance is observed at the 50-day SMA around $87.38. The current technical setup, characterized by prices below key short-term moving averages and neutral RSI, suggests that the stock may face headwinds in the immediate future, though the longer-term uptrend supported by the 200-day SMA remains intact.
ProTips
The stock's current position below its 50-day SMA and 20-day EMA suggests waiting for a technical breakout before initiating new positions.
Key Catalysts
BullishConsistent Earnings Beats
DexCom Inc. has a strong track record of exceeding analyst EPS estimates, as demonstrated by its latest report on July 30, 2026, where it beat estimates by 14.75%. This pattern suggests operational strength and effective execution.
Source: Company Earnings Reports
BullishStrong Analyst Conviction
The majority of analysts maintain a 'Buy' rating, with a median price target of $95.00, indicating significant Wall Street confidence in the company's future prospects.
Source: Wall Street Analysts
BullishAbove Sector Average Growth
DexCom's revenue growth of 13.1% surpasses the Healthcare sector median of 8.1%, highlighting its competitive advantage and market expansion capabilities.
Source: Company Financials
BearishModerate Insider Selling
Insiders have sold $16.1M worth of stock versus purchases of $1M, indicating a net selling trend that could signal caution among management regarding short-term price movements.
Source: Insider Transactions
BearishBelow Short-Term Moving Averages
The stock is trading below its 50-day SMA ($87.38) and 20-day EMA ($85.66), suggesting potential technical resistance and a possible short-term downtrend.
Source: Technical Analysis
Market Outlook
DexCom Inc. is expected to continue its growth trajectory, driven by strong product demand and a positive analyst outlook. The company's strong revenue growth, exceeding sector averages, and strong profitability metrics provide a solid foundation for future performance. Forward estimates indicate continued double-digit revenue growth and solid EPS expansion. Potential catalysts for upside include further market penetration of its continuous glucose monitoring systems and positive developments in its product pipeline. Conversely, risks such as the current technical resistance at the 50-day SMA and moderate insider selling could lead to short-term volatility. Investors should monitor competitive developments and the company's ability to maintain its growth momentum against these headwinds.
Key Statistics
Market Cap
32.10B
P/E Ratio
33.75
EPS (TTM)
2.52
Dividend Yield
0.00%
52 Week High
92.59
52 Week Low
54.11
As of October 14, 2026, DXCM trades at $83.45, with a market value of $32.10B and a P/E ratio of 33.75.
DexCom Inc. exhibits strong fundamental performance, with a current P/E ratio of 33.75, which is slightly above the Healthcare sector median of 31.9, but justified by its superior profitability metrics. The company boasts a net profit margin of 20.12% and an operating margin of 24.33%, significantly outperforming the sector median ROE of 6.9%. Its revenue growth of 13.1% also surpasses the sector median of 8.1%, indicating strong market adoption and expansion. The company's price-to-sales ratio stands at 6.46, which is higher than the sector median of 3.7, suggesting investors are willing to pay a premium for its sales, likely due to its high growth and profitability. The debt-to-equity ratio of 0.53 is within reasonable bounds for the sector. While the current valuation may appear stretched relative to some sector averages, the company's consistent earnings beats and strong growth prospects, coupled with strong margins and returns on equity, provide a solid foundation for its valuation.
Earnings & Growth Analysis
DexCom Inc. has demonstrated a consistent ability to beat analyst earnings expectations. In its most recent report on July 30, 2026, the company reported an EPS of $0.70, exceeding the estimate of $0.61 by 14.75% and leading to an 11.95% stock price increase. Prior quarters also show positive surprises, including a 19.15% EPS beat in April 2026 and a 4.62% beat in February 2026. While the October 2025 earnings report showed a 7.02% surprise, the stock experienced a decline of 14.63%, indicating that market reaction can be influenced by factors beyond the EPS beat itself. Overall, the earnings trend suggests strong operational performance and effective management in meeting or exceeding financial targets, providing a positive backdrop for the stock. Forward estimates for the current year project EPS of $2.66 and revenue growth of 12.00%, reinforcing the expectation of continued financial strength.
Key Risks
DexCom Inc. faces moderate selling pressure from insiders, with total sales of $16.1M versus purchases of $1M, indicating a degree of caution among management regarding near-term stock performance. Additionally, the stock is currently trading below its key short-term moving averages (50-day SMA and 20-day EMA), suggesting potential for further price depreciation or consolidation. Competitive pressures within the medical device sector, particularly in continuous glucose monitoring, could also impact future growth and market share.
Technical Indicators i
RSI (14-day)
41.34
MACD (12, 26)
-0.647
SMA (50-day)
87.38
SMA (200-day)
73.77
Technical RatingBearish
RSI
Neutral
SMA Cross
Bullish
Price vs SMA
Bearish
MACD
Bearish
Golden Cross in effect with the 50-day SMA ($87.38) above the 200-day SMA ($73.77), price is trading below the 50-day SMA.
As of October 14, 2026, with DXCM at $83.45, its 14-day RSI is 41.3 (neutral territory), its 50-day simple moving average is $87.38 and its 200-day is $73.77.
Calculated by CleaRank on daily closes as of October 14, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
S&P 500 (SPY)+0.36
Weak correlation
Nasdaq 100 (QQQ)+0.30
Weak correlation
Bitcoin (BTC)+0.07
Weak correlation
Gold (XAU)+0.04
Weak correlation
As of October 14, 2026, DXCM's 1-year correlation of daily returns is +0.36 with S&P 500 (SPY), +0.30 with Nasdaq 100 (QQQ), +0.07 with Bitcoin (BTC) and +0.04 with gold (XAU).
Check Custom Correlation
How does any other asset move with DXCM? One year of daily closes, Pearson correlation.
Try
DXCM Wall Street View
12-month price targets
Low $79.00Median $95.00 (+13.8%)High $115.00
Ratings
Buy 26Hold 3Sell 03 months ago: 25 of 28 buy
Recent rating actions
Recent analyst rating actions on DXCM
Date
Firm
Action
Rating
Oct 7, 2026
Barclays
Initiates
Overweight
Oct 1, 2026
RBC Capital
Maintains
Outperform
Sep 18, 2026
Truist Securities
Maintains
Buy
Sep 18, 2026
TD Cowen
Reiterates
Buy
Aug 4, 2026
Argus Research
Maintains
Buy
Aug 3, 2026
Canaccord Genuity
Maintains
Buy
As of October 14, 2026, 29 Wall Street analysts cover DXCM: 26 rate it a buy or strong buy, 3 a hold and 0 a sell or strong sell. Their 12-month price targets range from $79.00 to $115.00, with a median of $95.00, 13.8% above the price of $83.45.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
DXCM Trade Plans
Specific entry, exit, and risk management levels
Select Your Trade Bias
Risk Tolerance
Conservative2%Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →
Long entry pick an entry style
Conservative
$81.78
2% below current price (Pullback entry)
Lower risk, wait for pullback
Aggressive
$83.45
Buy at current price
Higher risk, immediate entry
Risk Management
STOP LOSS
$77.60
MAX LOSS
-5.1%
Volatility-Adjusted Stop Loss
Calculated based on RSI (41.3) and current market volatility
These levels come from DXCM's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Growth of $10,000
A $10,000 investment in DXCM in October 2016 would be worth about $41,655 today, compared with about $36,506 for the same investment in the S&P 500 benchmark.
Compare with Another Ticker
DXCM Drawdowns & Recovery
Worst fall, last 10 years
-65.8%
November 2021 to November 2025
Recovery
Not yet
still 48.0% below the November 2021 peak
From the 10-year high
-48.0%
highest close, November 2021
1-year holds that gained
60%
of every 1-year window
As of October 14, 2026, DXCM's worst peak-to-trough fall over the last 10 years was -65.8% (November 2021 to November 2025); it is still 48.0% below that peak, and 60% of 1-year holding periods ended with a gain.
From weekly closing values. A drawdown is the fall from the highest value reached so far to a later low.
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in DXCM today could grow to about $24,369 by 2036 in the base case, with a 90th-percentile outcome near $183,772 and a 10th-percentile outcome around $3,232. Projections are statistical simulations, not guarantees.
DXCM Stock Price Prediction: 2030
CleaRank's simulation projects a price near $119 for DXCM by 2030 in the base case, from $83.45 today (1.4x over 4 years). The 10th-percentile path ends near $33.21. These are outcomes of a Monte Carlo simulation run on DXCM's historical return distribution, not price targets, and they assume no dividends are reinvested.
DXCM simulated price paths by year
Year
10th percentile
Base case
90th percentile
2027
$48.16
$91.22
$173
2028
$40.40
$99.72
$246
2029
$36.05
$109
$330
2030
$33.21
$119
$428
2031
$31.22
$130
$544
Method: a lognormal simulation of DXCM's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. DXCM is highly volatile, so its upside column reaches an extreme multiple; treat it as a statistical tail, not an expectation.
As of October 14, 2026, DXCM insiders reported 38 open-market sales worth $16.1M and 1 open-market purchase worth $1.0M over the last 18 months; grants and option exercises are not counted.
Recent insider transactions in DXCM
Date
Insider
Type
Shares
Value
Sep 28, 2026
STERN SADIE
Officer
Sell
2.6K
$221.0K
Sep 15, 2026
AUGUSTINOS NICHOLAS
Director
Sell
8.1K
$679.8K
Sep 15, 2026
BROWN MICHAEL JON
Officer
Sell
1.7K
$142.9K
Sep 10, 2026
SYLVAIN JEREME M
Chief Financial Officer
Sell
3.6K
$302.9K
Sep 10, 2026
BOEHNLEIN GLENN S
Director
Grant
5.8K
-
Aug 27, 2026
STERN SADIE
Officer
Sell
2.6K
$226.7K
Aug 20, 2026
SAYER KEVIN R
Officer and Director
Sell
26.8K
$2.4M
Aug 14, 2026
BROWN MICHAEL JON
Officer
Sell
1.7K
$156.3K
Aug 12, 2026
HELLER BRIDGETTE P
Director
Sell
1.0K
$89.3K
Aug 12, 2026
AUGUSTINOS NICHOLAS
Director
Grant
1.1K
-
Page 1 of 1
Frequently Asked Questions
What are the biggest risks facing DexCom Inc.?
Key risks include moderate insider selling totaling $16.1M, the stock trading below its 50-day SMA and 20-day EMA, and potential competitive pressures within the medical device market. These factors suggest potential short-term headwinds.
How has DexCom Inc. performed in recent earnings reports?
DexCom Inc. has a strong history of beating earnings estimates. Its latest report on July 30, 2026, showed an EPS beat of 14.75%, leading to an 11.95% stock price increase. Previous quarters also demonstrated positive earnings surprises.
What is DexCom Inc.'s valuation compared to its sector peers?
DexCom Inc.'s P/E ratio of 33.75 is slightly higher than the Healthcare sector median of 31.9. However, its profit margin of 20.12% and ROE of 38.49% significantly exceed sector averages, justifying its premium valuation.
What is the outlook for DexCom Inc.'s revenue growth?
Analysts project strong revenue growth for DexCom Inc., with an expected 11.00% increase next quarter and 12.00% for the current year. Long-term growth estimates also remain strong, with a projected 17.4% increase next year and an average of 22.5% annually over the next five years.
How does DexCom Inc.'s technical analysis look currently?
Technically, DexCom Inc. is in a mixed position. It trades below its 50-day SMA and 20-day EMA but above its 200-day SMA. The 14-day RSI is neutral at 41.34, and the MACD is negative, suggesting potential short-term weakness while the long-term trend remains supported.
Are insiders buying or selling DXCM?
Selling, on balance. In the last 18 months, DXCM's officers, directors and large holders reported 38 sales worth $16.1M and 1 open-market purchase worth $1.0M. Grants and option exercises are not counted as buying.
What is the analyst price target for DXCM?
As of October 14, 2026, the 29 Wall Street analysts covering DXCM have 12-month targets from $79.00 to $115.00, with a median of $95.00, 13.8% above the current price of $83.45. 26 rate it a buy or strong buy, 3 a hold and 0 a sell or strong sell. Three months ago 25 of 28 rated it a buy.
What is DXCM's biggest drop in the last 10 years?
DexCom Inc. (DXCM)'s worst peak-to-trough fall over the last 10 years was -65.8%, from November 2021 to November 2025. It has not regained that peak yet and is still 48.0% below it. Over the same period, 60% of 1-year holding periods ended with a gain.
What are DXCM's best and worst months?
Over the last 10 years, July has been DXCM's strongest month on average (+6.80%, rising in 7 of 10 years) and September its weakest (-8.62%, rising in 2 of 10 years). Seasonal averages describe the past and do not predict a given year.
How closely does DXCM move with the stock market?
Over the past year DXCM's daily returns were weakly correlated with the S&P 500 (SPY) (+0.36). Nasdaq 100 (QQQ): +0.30; Bitcoin (BTC): +0.07; Gold (XAU): +0.04. A figure near +1 means the two usually move together; near 0 means little relationship.
